2024-02-22 15:25:04 ET
Genus plc (GENSF)
Q2 2024 Earnings Conference Call
February 22, 2024 02:05 AM ET
Company Participants
Jorgen Kokke - CEO
Alison Henriksen - CFO
Conference Call Participants
Presentation
Jorgen Kokke
Good morning, everyone, and thank you for joining us today. I am Jorgen Kokke, and I am the CEO of Genus plc. Today, we'll be reviewing our FY 2024 Interim Results covering the six months period to December 2023.
I will start off by giving an overview of our markets over the period and the actions we are taking on our strategic priorities. Alison will then take you through the half year financials, before turning it back to me to provide more details on the progress we are making on each of our strategic priorities and the outlook for the remainder of the fiscal year.
In November at our Capital Markets Day, I shared our four strategic priorities. These remain our focus and we are accelerating their delivery. Our first priority is that we continue to grow porcine with more stable growth from China. Here, I want to remind you of the resiliency of our PIC ex-China business, which continues to grow through gaining market share despite challenging market conditions.
In China, despite these conditions, we're making commercial progress winning new royalty customers in the first half and we even have signed more new customers in January of 2024 as well.
Our second priority is successful commercial delivery of PRP, the PRRSv gene edit. Since our trading update last week, the FDA has notified us that it has accepted our phenotypic and our genotypic durability submissions. This is great news and it demonstrates the progress we are making.
Our engagement with the FDA has shifted to post-approval compliance, which is also very encouraging. We are now expecting FDA approval in fiscal year 2025. Our commercialization plans are on track and unchanged....
Read the full article on Seeking Alpha
For further details see:
Genus plc (GENSF) Q2 2024 Earnings Call Transcript